Will the FDA change how it vets treatments following the Alzheimer's drug debacle?

Will the FDA change how it vets treatments following the Alzheimer’s drug debacle?

Nature, Published online: 13 May 2022; doi:10.1038/d41586-022-01316-8

The accelerated approval of aducanumab has triggered US lawmakers to push for more oversight from the agency.
Source: Nature